Adjusted Attributable Fraction for Hypertension by Specific Cancer Therapies Considered as Risk Factors Using the Children’s Oncology Group Guidelines and the PRS Among Survivors
The adjusted attributable fraction for hypertension due to both PRS and the specific cancer therapies was 40.2% (21.0% attributed to the PRS; 15.7% attributable to cancer therapies; and the remaining 3.5% due to the joint effect of both cancer therapies and the PRS together, exceeding the individual effects of the 2). The contribution of the PRS remained generally consistent across the subgroups based on body mass index, age, and exposure to hypothalamic-pituitary axis radiation. PRS = polygenic risk score.